Approval
FDA grants accelerated approval to subcutaneous amivantamab in head and neck cancer
Johnson & Johnson's Rybrevant Faspro won US accelerated approval as a single agent for head and neck squamous cancer that has recurred or spread after platinum chemotherapy and a PD-(L)1 antibody, excluding HPV-linked oropharyngeal tumours. In the OrigAMI-4 cohort of 102 patients, 42% responded. Serious adverse reactions hit 39%, and full approval may hinge on the OrigAMI-5 trial.
Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.
